Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests

By LabMedica International staff writers
Posted on 03 Oct 2008
Interleukin Genetics, Inc. More...
(Waltham, MA, USA), and Access Business Group International LLC (Ada, MI, USA), a division of Alticor Inc., have reached an agreement that will increase access to all intellectual property related to genetic tests jointly developed by Interleukin Genetics and Access Business Group under their research agreements.

In turn, this will permit the expansion of Interleukin Genetics' distribution network for such genetic tests. Under the agreement, Access Business Group's existing license to the Interleukin Genetics' intellectual property will become non-exclusive.

Interleukin Genetics will have the right to brand, market, sell, and distribute all genetic tests developed using its existing and future intellectual property, either itself or through additional third-party licensees. Access Business Group will continue to distribute the Heart Health and General Nutrition genetic tests under the Gensona brand name.

The agreement will continue to allow Interleukin Genetics to have exclusive ownership of all inventions relating to genetic tests arising from research programs between the companies. Lewis H. Bender, chief executive officer at Interleukin Genetics, commented, "This is an excellent agreement for Interleukin Genetics as we now have the opportunity to aggressively pursue new partnerships for distribution of the genetic tests and intellectual property created over the years with our partner, Access Business Group. We are excited to continue our current efforts to out-license our intellectual property to companies in the biotechnology, molecular diagnostic, pharmaceutical, direct sales, and consumer products areas.”

Interleukin Genetics is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics currently offers an array of Nutraceuticals and OTCeuticals, including Ginkoba, Ginsana, and Venastat, which are sold at the US's largest food, drug, and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment.

Related Links:
Interleukin Genetics
Access Business Group International



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.